Milestone from Gedeon Richter as Palatin initiates Ph III bremelanotide study

31 December 2014

US biopharma company Palatin Technologies (NYSE MKT: PTN) says it has started its bremelanotide pivotal registration program, initiating its Phase III reconnect study in the USA for the treatment of female sexual dysfunction (FSD).

The start of the reconnect study in the USA triggers a development milestone payment of 2.5 million euros ($3 million) from Hungary’s largest drugmaker Gedeon Richter (RICHT: HB), Palatin's partner in Europe for bremelanotide for FSD. Palatin is also eligible to receive regulatory and sales milestones, and low double-digit royalties on net sales in the European licensed territory. Under the terms of the deal, Palatin is eligible for as much as 90 million euros in milestones and double-digit royalties.

"We are pleased to achieve this major milestone in the bremelanotide program with the initiation of our Phase III reconnect study in the USA," stated Carl Spana, president and chief executive of Palatin, adding: "This is a key step in our global strategy to bring bremelanotide to market for the millions of women who have FSD and are seeking a safe and effective treatment."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK